Seattle Institute For Biomedical And Clinical Research

Alpha Cognition reported Q3 2024 financials: $4.5M raised in bridge financing, FDA approval for Alzheimer's treatment ZUNVEYL (launch Q1 2025), successful stability tests extending ZUNVEYL's shelf life to 24 months, and NASDAQ listing preparation. Financials: Q3 2024 R&D expenses $1.0M (down from $1.4M in Q3 2023), G&A expenses $1.2M (up from $0.8M), net loss $1.9M ($0.31 per share). Cash position: $3.7M as of September 30, 2024.

Alpha Cognition Inc. reported Q2 and six-month financial results, highlighting FDA approval for ZUNVEYL, a novel Alzheimer's treatment. The company raised $4.5M, advanced commercialization for a Q1 2025 launch, and completed NASDAQ listing preparations. R&D expenses decreased due to completed ZUNVEYL trials. Net loss for Q3 2024 was $1.9M, with cash at $3.7M.